
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is a promising company in the clinical-stage biopharmaceutical industry, with a novel approach to developing treatments for central nervous system disorders. Although their once-daily regimen for ML-007C-MA did not meet statistical significance on the primary endpoint, the drug still showed numerical improvement and separation on several secondary endpoints in their Phase 2 ZEPHYR trial. The company plans to engage with the FDA to discuss the path forward for ML-007C-MA and has sufficient funding to continue their comprehensive development plans. While the next catalyst for the company will be the top-line data from their VISTA trial in 2027, there is also the potential for positive readthroughs from data on similar drugs being developed by other companies.
Bears say
MapLight Therapeutics is facing several fundamental challenges that could hinder its long-term growth and profitability. These include a pipeline that is focused on difficult-to-treat neuropsychiatry and neurodegenerative conditions, high risks of trial failures, potential lack of FDA acceptance and approvals, and dilutive capital raising activities. Additionally, the company may face intense competition, pricing pressure, and insufficient resources for successful commercialization, which could impact its performance and long-term viability.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares